Your browser doesn't support javascript.
loading
Hypothetical intervention of targeted systolic blood pressure control of < 120 mmHg on renal prognosis for persons with stage 3-4 chronic kidney disease: an application of parametric g-formula using health checkup data in Japan.
Takeuchi, Masato; Shinkawa, Kanna; Yanagita, Motoko; Kawakami, Koji.
  • Takeuchi M; Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. takeuchi.masato.3c@kyoto-u.ac.jp.
  • Shinkawa K; Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
  • Yanagita M; Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kawakami K; Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Clin Exp Nephrol ; 27(6): 542-547, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36947305
ABSTRACT

BACKGROUND:

The revised KDIGO guidelines recommend maintaining systolic blood pressure (sBP) < 120 mmHg in patients with chronic kidney disease (CKD), based on cardiovascular and survival benefits. However, the renal benefit of this strategy remains less clear.

METHODS:

We used data of routine health checkups in Japan. Persons whose estimated glomerular filtration rate (eGFR) was < 60 mL/min/1.73 m2 in 2015 without end-stage disease were followed until 2020. We estimated the 5-year benefit of hypothetical targeted sBP control using parametric g-formula modeling, accounting for both time-fixed and time-varying confounding variables. Four sensitivity analyses, including analysis using a marginal structural model (MSM) and positive control outcome analysis, were also done.

RESULTS:

We enrolled 28,972 persons with CKD (median age 54 years, male 69%, baseline eGFR [median] 56 mL/min/1.73m2). As compared with the natural course without a targeted intervention, there was no renoprotective effect of targeted sBP control, with a 5-year difference in eGFR of 0.65 mL/min/1.73 m2 (95% confidence interval - 0.42 to 1.65 mL/min/1.73 m2). MSM analysis found a similar result. In contrast, the positive control analysis using the cardiovascular outcome showed that targeted sBP control would reduce the cardiovascular disease incidence by 6.0% over 5 years.

CONCLUSIONS:

A targeted sBP control strategy maintaining < 120 mmHg may not yield a renoprotective effect for patients with stage 3-4 CKD, although it was expected to offer a cardiovascular benefit. Future research may be warranted in higher-risk populations, such as elderly people or those with more advanced kidney disease.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Hipertensión Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Hipertensión Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2023 Tipo del documento: Article